Wide Ranks

CTLT

Catalent, Inc.

61.00

Top Statistics
Market Cap 11 B Forward PE 35.00 Revenue Growth 4.20 %
Current Ratio 2.51 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -9.34 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 33.95 Enterprise / Revenue 3.55 Price To Sales Trailing12 Months 2.50
Profitability
Profit Margins -9.34 % Operating Margins -6.94 %
Balance Sheet
Total Cash 335 M Total Cash Per Share 1.85 Total Debt 4 B
Total Debt To Equity 139.67 Current Ratio 2.51 Book Value Per Share 19.52
All Measures
Short Ratio 487.00 % Message Board Id finmb_83345566 Fax 732 537 6480
Shares Short Prior Month 8 M Return On Equity -0.1119 City Somerset
Uuid 374827dc-d5d8-3847-9eca-63240d94c654 Previous Close 60.75 First Trade Date Epoch Utc 1 B
Book Value 19.52 Beta 1.16 Total Debt 4 B
Volume 1 M Price To Book 3.13 Fifty Two Week Low 36.74
Total Cash Per Share 1.85 Total Revenue 4 B Shares Short Previous Month Date 1 B
Target Median Price 63.50 Max Age 86400 Recommendation Mean 3.00
Sand P52 Week Change 0.3133 Operating Margins -6.94 % Target Mean Price 63.43
Net Income To Common -413000000 Ask 61.00 Short Percent Of Float 0.0563
Implied Shares Outstanding 181 M Last Fiscal Year End 1 B Trailing Peg Ratio 50833.33 %
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 335 M
Next Fiscal Year End 1 B Revenue Per Share 24.40 Held Percent Insiders 0.0050
Ebitda Margins 10.45 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 60.75 Target Low Price 63.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 59.86 Open 60.95
Free Cashflow 364 M State NJ Dividend Yield 0.00 %
Return On Assets -0.0018 Time Zone Short Name EST Trailing Eps -2.28
Day Low 60.70 Address1 14 Schoolhouse Road Shares Outstanding 181 M
Price Hint 2 Target High Price 63.50 Website https://www.catalent.com
52 Week Change 0.5701 Average Volume 1 M Forward Eps 1.76
Recommendation Key hold Compensation As Of Epoch Date 1 B Quick Ratio 169.00 %
Is_sp_500 True Regular Market Day High 61.05 Profit Margins -9.34 %
Debt To Equity 139.67 Fifty Two Week High 61.50 Day High 61.05
Shares Short 9 M Regular Market Open 60.95 Industry Key drug-manufacturers-specialty-generic
Bid 60.76 Earnings Growth 0.00 % Enterprise To Revenue 3.55
Revenue Growth 4.20 % Shares Percent Shares Out 0.0499 Operating Cashflow 399 M
Currency USD Time Zone Full Name America/New_York Market Cap 11 B
Is_nasdaq_100 False Zip 08873 Quote Type EQUITY
Industry Drug Manufacturers - Specialty & Generic Long Name Catalent, Inc. Regular Market Day Low 60.70
Held Percent Institutions 0.8778 Current Price 61.00 Enterprise To Ebitda 33.95
Financial Currency USD Current Ratio 2.51 Gross Margins 21.82 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 7 Country United States
Float Shares 180 M Two Hundred Day Average 57.90 Enterprise Value 15 B
Price To Sales Trailing12 Months 2.50 Forward PE 35.00 Regular Market Volume 1 M
Ebitda 462 M Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide.

It operates in two segments, Biologics, and Pharma and Consumer Health.

The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms.

This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices.

The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions.

It serves biotechnology, pharmaceutical, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries.

The company was founded in 1933 and is headquartered in Somerset, New Jersey.